{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16600","value":"18600"},{"groupId":"OG001","spread":"1790","value":"5650"}]}],"title":"Cycle 1 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6600","value":"19500"},{"groupId":"OG001","spread":"5060","value":"14900"}]}],"title":"Cycle 1 day 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"AMG 176 plasma concentrations with values below the limit of quantification were set to zero. Pharmacokinetic (PK) parameters were determined from the time concentration profile using noncompartmental analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received IV AMG 176 at dose level 1 once a week in 28-day cycles. Treatment was planned until disease progression or unacceptable toxicity.","id":"OG000","title":"Part 1A Dose Exploration: AMG 176 Dose Level 1"},{"description":"Participants received IV AMG 176 at dose level 1 on cycle 1 day 1 and then dose level 2 from cycle 1 day 8 and once a week thereafter (each cycle = 28 days). Treatment was planned until disease progression or unacceptable toxicity.","id":"OG001","title":"Part 1A Dose Exploration: AMG 176 Dose Level 1 Then Dose Level 2"}],"paramType":"MEAN","populationDescription":"The PK analysis set included all participants who received at least 1 dose of AMG 176 and had at least 1 PK sample collected.","reportingStatus":"POSTED","timeFrame":"Cycle 1: pre-dose, end of infusion (EOI), 3, 5, 7, 8, 24 hours post-infusion in weeks 1 and 2; pre-dose, EOI, 8 and 24 hours post-infusion in cycle 1 weeks 3 and 4","title":"Maximum Plasma Concentration (Cmax) of AMG 176","type":"SECONDARY","unitOfMeasure":"ng/mL"}